摘要
质子泵抑制剂可以明显降低急性冠状动脉综合征及经皮冠状动脉介入术后双联抗血小板治疗患者的出血风险,但近年来的研究显示氯吡格雷与质子泵抑制剂相互作用可能导致主要心血管不良事件的增加,对临床工作造成了困扰。现重点阐述P2Y12受体拮抗剂与质子泵抑制剂相互作用的研究进展,并为临床决策提供建议。
Proton pump inhibitors are used to prevent gastrointestinal bleeding from dual-antiplatelet therapy, which reduces major cardiovascular events for patients with acute coronary syndromes and in patients undergoing percutaneous coronary interventions. Over the last few years, conflicting evidence has shown that interactions between clopidegrel and proton pump inhibitors might have contributed to the increased risk of major cardiovascular events. This review focuses on the updates of the current evidences between P2Y12 receptor antagonists and proton pump inhibitors and provides practical implications for clinical practice.
出处
《心血管病学进展》
CAS
2015年第5期570-574,共5页
Advances in Cardiovascular Diseases
基金
国家"十二五"科技支撑计划(2011BAI11B07)
